Cargando…

Quality of life in patients with heart failure and improved ejection fraction: one‐year changes and prognosis

AIMS: The criteria for patients with heart failure (HF) and improved ejection fraction (HFimpEF) are a baseline left ventricular ejection fraction (LVEF) ≤40%, a ≥10‐point increase from baseline LVEF, and a second LVEF measurement >40%. We aimed to (i) assess patients with HF and reduced LVEF (HF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zamora, Elisabet, González, Beatriz, Lupón, Josep, Borrellas, Andrea, Domingo, Mar, Santiago‐Vacas, Evelyn, Cediel, Germán, Codina, Pau, Rivas, Carmen, Pulido, Ana, Crespo, Eva, Velayos, Patricia, Diaz, Violeta, Bayes‐Genis, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773756/ https://www.ncbi.nlm.nih.gov/pubmed/35916351 http://dx.doi.org/10.1002/ehf2.14098

Ejemplares similares

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Gender-Related Differences in Heart Failure Biomarkers
por: Cediel, Germán, et al.
Publicado: (2021)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Lung ultrasound in outpatients with heart failure: the wet‐to‐dry HF study
por: Domingo, Mar, et al.
Publicado: (2021)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators
por: Codina, Pau, et al.
Publicado: (2022)

Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality
por: Spitaleri, Giosafat, et al.
Publicado: (2022)

Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018
por: Spitaleri, Giosafat, et al.
Publicado: (2021)

Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
por: Rodríguez-Calvo, Ricardo, et al.
Publicado: (2023)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
por: Julián, María Teresa, et al.
Publicado: (2020)

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny
por: Bayes-Genis, Antoni
Publicado: (2022)

Circulating monocyte subsets and heart failure prognosis
por: Elchinova, Elena, et al.
Publicado: (2018)

Impact of a ‘stent for life’ initiative on post‐ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience
por: Bayes‐Genis, Antoni, et al.
Publicado: (2017)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Nutritional Status According to the GLIM Criteria in Patients with Chronic Heart Failure: Association with Prognosis
por: Joaquín, Clara, et al.
Publicado: (2022)

Weight Loss in Obese Patients With Heart Failure
por: Zamora, Elisabet, et al.
Publicado: (2016)

Can Natriuretic Peptides be Used to Guide Therapy?
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain)
por: Farré, Nuria, et al.
Publicado: (2017)

Determination of HLA‐A, ‐B, ‐C, ‐DRB1 and ‐DQB1 allele and haplotype frequencies in heart failure patients
por: Roura, Santiago, et al.
Publicado: (2019)

Impact of diabetes on the predictive value of heart failure biomarkers
por: Alonso, Nuria, et al.
Publicado: (2016)

Thirst distress in outpatients with heart failure in a Mediterranean zone of Spain
por: Eng, Sanna Hagelberg, et al.
Publicado: (2021)

Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
por: Lupón, Josep, et al.
Publicado: (2014)

Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification
por: Zamora, Elisabet, et al.
Publicado: (2012)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients
por: Pacho, Cristina, et al.
Publicado: (2018)

Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme
por: Gastelurrutia, Paloma, et al.
Publicado: (2016)

Prognostic Value of New‐Generation Troponins in ST‐Segment–Elevation Myocardial Infarction in the Modern Era: The RUTI‐STEMI Study
por: Cediel, Germán, et al.
Publicado: (2017)

Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?
por: Domingo, Mar, et al.
Publicado: (2020)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
por: Miñana, Gema, et al.
Publicado: (2020)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Pascual-Figal, Domingo, et al.
Publicado: (2021)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study
por: Revuelta‐López, Elena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r0bj9t2urkk8duj9fek8bt3aik